Monday, 11 Aug 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    10/08/2025
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    10/08/2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    09/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    NOTICE OF SETTLEMENT APPROVAL
    09/08/2025
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    09/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Business

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions

Business Wire
Last updated: 21/06/2025 1:52 PM
Business Wire
Share
5 Min Read
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
SHARE
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
  • Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration.
  • Preclinical data on VRB-103, Verdiva Bio’s once-weekly, oral amylin analog, supports continued development, both as a monotherapy and as a single tablet co-formulation with VRB-101.

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–#ADA85–Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva’s investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions.

- Advertisement -




- Advertisement -

“Our first data presentation as Verdiva Bio at the prestigious ADA meeting marks a key milestone for our team. These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies,” stated Dr. Mohamed Eid, CMO at Verdiva.

“The early clinical and preclinical data not only show the potential of these compounds individually, but also the additive effect they may have in combination, highlighting the flexibility of our modular portfolio approach. At Verdiva Bio, we are committed to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications. We’re excited about the potential of our once-weekly oral peptide candidates to help address this global health challenge.”

- Advertisement -

VRB-101: An investigational once-weekly oral GLP-1 analog

- Advertisement -

This presentation highlights new clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1RA formulated with Verdiva’s clinically validated, proprietary oral delivery technology T2026. Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1RA therapies. These findings support continued investigation of VRB-101 as a potential once-weekly, scalable oral therapeutic option for both weight reduction and long-term weight maintenance, with the potential to exert potent weight reduction and may improve adherence via a more patient-friendly dosing regimen.

Poster Presentation #069

Title: VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential

Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time

Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center

- Advertisement -

VRB-103: Efficacy of novel once-weekly oral amylin analog as a monotherapy, and in combination with VRB-101 in vivo

- Advertisement -

A second presentation will share novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101. In preclinical models, the rationally designed peptide combination showed an additive effect on body weight reduction. Additionally, co-formulation of these peptides in a single tablet with T2026 maintained comparable plasma exposure for both compounds. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101.

Poster Presentation #068

Title: Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures

Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time

Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center

- Advertisement -

About Verdiva Bio

- Advertisement -

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

For more information, please visit www.verdivabio.com.

- Advertisement -

Contacts

- Advertisement -

Verdiva Bio
Charlotte Davison, Chief of Staff

info@verdivabio.com

Vigo Consulting (Media)
Melanie Toyne-Sewell

Rozi Morris

+44 20 7390 0230

VerdivaBio@VigoConsulting.com

- Advertisement -
AutoScheduler Receives 2025 Top Supply Chain Projects Award
Sidetrade charts its course in responsible AI with the publication of its 2024 CSR report
Football fans in the UK will be able to watch every match of this summer’s FIFA Club World Cup FREE on DAZN – with an all-star team of legends and top pundits bringing them all the action
NYSE Content Advisory: Pre-Market update + Fed Decision on deck
Global Consortium Led by Nexus Core Systems to Build AI Factory Powered by 500 MW of Renewable Energy and Next-Generation AI Compute
TAGGED:adaamylinbiobiopharmaceuticalcandidatescardiometabolicclinicalclinicalstagecompanycompoundsdatadevelopingdisordersfocusedfranciscobusinessinnovativelimitedlondonobesityonceweeklyoralpeptidepotentialpresentsanshowcasingtherapiesverdivawillwireadaverdiva
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

HDFC Life Celebrates 25th AGM; Chairman Keki Mistry Highlights Industry Potential and Strong Company Performance
Business

HDFC Life Celebrates 25th AGM; Chairman Keki Mistry Highlights Industry Potential and Strong Company Performance

17/07/2025
Medit to Reveal New Medit i900 Mobility, Powered by True Mobility
Entertainment

Medit to Reveal New Medit i900 Mobility, Powered by True Mobility

01/08/2025
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Health

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

09/07/2025
DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
Business

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

02/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?